Daunorubicin reduces cardiomyopathy risk compared with doxorubicin in childhood cancer survivors
Daunorubicin appeared associated with a lower cardiomyopathy risk than doxorubicin among childhood cancer survivors, according to a multicenter cohort study published in JAMA Oncology.